Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Condensed Consolidated Statements of Operations
Net Revenues	$ 83,821	$ 52,061	$ 222,153	$ 155,207
Operating Expenses
Cost of sales (excluding depreciation and amortization)	32,894	24,413	102,459	66,712
Research and development	7,657	2,456	17,096	8,229
Selling, general, and administrative	30,081	17,181	90,856	53,588
Depreciation and amortization	14,167	11,346	42,488	33,568
Contingent consideration fair value adjustment	2,476		2,134	0
Legal settlement expense			0	8,400
Purified Cortrophin Gel pre-launch charges		227	0	780
Restructuring activities	1,541		4,111	0
Intangible asset impairment charge		0	112	0
Total Operating Expenses	88,816	55,623	259,256	171,277
Operating Loss	(4,995)	(3,562)	(37,103)	(16,070)
Other Expense, net
Interest expense, net	(7,264)	(2,497)	(20,546)	(7,482)
Other income/(expense), net	37	(1,071)	712	(1,653)
Loss Before Benefit for Income Taxes	(12,222)	(7,130)	(56,937)	(25,205)
Benefit for income taxes	3,622	2,683	13,284	6,738
Net Loss	(8,600)	(4,447)	(43,653)	(18,467)
Dividends on Series A Convertible Preferred Stock	(406)		(1,218)	0
Net Loss Available to Common Shareholders	$ (9,006)	$ (4,447)	$ (44,871)	$ (18,467)
Basic and Diluted Loss Per Share:
Basic Loss Per Share	$ (0.55)	$ (0.37)	$ (2.76)	$ (1.53)
Diluted Loss Per Share	$ (0.55)	$ (0.37)	$ (2.76)	$ (1.53)
Basic Weighted-Average Shares Outstanding	16,303	12,107	16,238	12,066
Diluted Weighted-Average Shares Outstanding	16,303	12,107	16,238	12,066